We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
214 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Roche Products Pty Ltd - Ophthalmic anaesthesia needle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EVRYSDI risdiplam 5 mg tablet blister pack.
-
Australian public assessment report (AusPar)ITOVEBI (inavolisib), in combination with palbociclib and fulvestrant, is for the treatment of adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine therapy.
-
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OCREVUS ocrelizumab 920 mg/23 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ITOVEBI inavolisib 3 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ITOVEBI inavolisib 9 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Roche Products Pty Ltd - Medication transfer set.
-
Apr-2025Prescription medicine evaluationActive ingredient: obinutuzumab.